Entero Therapeutics, Inc.
ENTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $5 | $1 | $38 |
| G&A Expenses | $0 | $11 | $12 | $18 |
| SG&A Expenses | $0 | $11 | $12 | $18 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $1 |
| Operating Expenses | $0 | $16 | $13 | $57 |
| Operating Income | -$0 | -$16 | -$13 | -$59 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$0 | -$2 | -$2 |
| Pre-Tax Income | -$0 | -$16 | -$15 | -$59 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$18 | -$16 | -$15 | -$59 |
| % Margin | – | – | – | – |
| EPS | -3.88 | -46.96 | -407.37 | -27,544.98 |
| % Growth | 91.7% | 88.5% | 98.5% | – |
| EPS Diluted | -5.26 | -46.96 | -407.37 | -27,544.98 |
| Weighted Avg Shares Out | 5 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 3 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | $0 | -$16 | -$15 | -$58 |
| % Margin | – | – | – | – |